Polyarteritis nodosa

Introduction

Polyarteritis nodosa (often abbreviated as PAN) is a rare but potentially serious form of systemic vasculitis that primarily affects medium-sized arteries. It can lead to inflammation of blood vessel walls, which in turn may cause organ damage or dysfunction. Though uncommon—affecting roughly 3 to 4 people per million each year—its impact on daily life can be significant, from persistent fevers and fatigue to more acute issues like abdominal pain or neuropathy. In this article we’ll take you through the main symptoms of polyarteritis nodosa, explore its causes, discuss how doctors make a definitive diagnosis, review evidence-based treatment strategies, and give you a realistic outlook on long-term management.

Definition and Classification

At its core, polyarteritis nodosa is defined as a necrotizing vasculitis of medium-sized muscular arteries, characterized by segmental inflammation (i.e. only parts of the vessel are involved) and the formation of tiny nodules or aneurysms in the vessel wall. It’s classified under systemic vasculitides and is considered non–ANCA–associated—unlike some small vessel vasculitis types. Clinically, PAN can be acute or chronic, and although most cases are considered idiopathic (unknown cause), a subset is linked to hepatitis B virus infection.

• Acute PAN: rapid onset, high systemic inflammation
• Chronic PAN: insidious progression over months, more subtle signs
• Hepatitis B–associated PAN: accounts for ~10% of cases, often shows immune complex deposits
• Childhood-onset PAN: rare but recognized, tends to have more skin and joint involvement

It mainly targets arteries supplying skin, kidneys, gastrointestinal tract, peripheral nerves, and muscles. You won’t usually see involvement of pulmonary arteries—that’s more typical of other vasculitides.

Causes and Risk Factors

Understanding the exact causes of polyarteritis nodosa remains a challenge. Broadly, we divide triggers into infectious, immune-mediated, genetic, and environmental factors.

Infectious associations: Roughly one in ten PAN cases correlates with hepatitis B, possibly from immune complex formation and deposition in vessel walls. Less commonly, hepatitis C or streptococcal infections have been implicated. For instance, I once saw a patient whose PAN flared soon after a poorly treated strep throat—odd, but true.

Immune-mediated elements: Autoantibodies and immune complex deposition can drive the inflammatory cascade in the vessel lining. Unlike ANCA-positive vasculitis, classic PAN rarely shows these antibodies in blood tests, but complement activation is often noted.

Genetic risk factors: While there’s no single “PAN gene,” family studies suggest a slight clustering in certain HLA types, hinting at inherited predispositions. Yet, most people with these HLA markers never develop the disease—so it’s not destiny, just one piece of the puzzle.

Environmental and lifestyle factors: Although less studied, heavy smoking or long-term silica exposure have been mooted as possible aggravators. However, solid evidence is still lacking.

• Non-modifiable risks: Age (peak incidence in 40–60 years), male sex, certain HLA types, hepatitis B infection history
• Modifiable risks: Smoking cessation might help dampen vascular inflammation; controlling viral hepatitis with antivirals reduces risk of HBV-associated PAN

In many cases, the root cause remains speculative, and researchers are still unraveling the precise triggers. So, yes, some uncertainty persists.

Pathophysiology (Mechanisms of Disease)

To understand how polyarteritis nodosa develops, let’s look at the vessel wall: Normally, medium-sized arteries have three layers—intima (inner), media (middle muscular layer), and adventitia (outer). In PAN, immune complexes or other inflammatory stimuli lead to infiltration of neutrophils, monocytes, and some lymphocytes into the vessel wall.

This infiltration results in:

• Fibrinoid necrosis: essentially, damage to the vessel wall where fibrin and immune mediators accumulate, making the wall brittle.
• Formation of microaneurysms: small bulges that can rupture or cause localized ischemia if they thrombose.
• Thrombosis and narrowing: clots can form in these inflamed segments, further reducing blood flow to downstream tissues.

When you have segmental inflammation, you get a “patchwork” of healthy and diseased areas—hence why symptoms can be so varied. In the kidney, this may lead to renovascular hypertension; in the gut, it can cause ischemic abdominal pain; in nerves, it shows up as neuropathy.

Importantly, PAN spares the pulmonary circulation—so if you see lung involvement, think about alternative diagnoses. This selective involvement underscores that pathophysiology isn’t random but follows vessel size and structural susceptibilities.

Symptoms and Clinical Presentation

The clinical picture of polyarteritis nodosa can be quite protean (fancy word for variable). Some patients present with constitutional symptoms first, while others come in for organ-specific complaints. Below is a rough timeline:

• Early/general: low-grade fever, fatigue, weight loss (often mistaken for flu or depression). One friend joked, “It felt like the worst hangover, but it’s been three months…”
• Cutaneous signs: tender nodules under the skin, livedo reticularis (that lace-like purple pattern), or small ulcers—remember to check extremities.
• Neurological: mononeuritis multiplex—sudden foot drop or wrist drop from peripheral nerve infarction. Painful, and sometimes misdiagnosed as diabetic neuropathy.
• Renal: hypertension from narrowing of renal arteries, mild proteinuria, but usually not the glomerulonephritis you see in ANCA vasculitis.
• Gastrointestinal: postprandial pain (“intestinal angina”), nausea, possible GI bleeding or perforation in severe cases.
• Cardiac: though rare, coronary artery involvement can lead to chest pain resembling angina.
• Musculoskeletal: arthralgias or myalgias, especially in calves or thighs.

Advanced disease may involve multiple systems simultaneously, raising the stakes for organ failure. Warning signs not to ignore include sudden severe abdominal pain, signs of acute limb ischemia (cold, pale extremity), or rapidly worsening neuropathy.

Be aware, though—symptoms vary widely from one person to another. That’s why polyarteritis nodosa is sometimes called a “great imitator.”

Diagnosis and Medical Evaluation

Diagnosing PAN is a stepwise process combining clinical suspicion, laboratory tests, imaging, and often tissue biopsy.

• Initial blood work: CBC may show anemia or leukocytosis, elevated ESR/CRP signaling inflammation, normal ANCA (helps differentiate from microscopic polyangiitis).
• Serology: test for hepatitis B surface antigen and DNA if positive; check complement levels—often low.
• Imaging: angiography (CT or MR angiogram) can reveal microaneurysms or segmental stenoses in renal, mesenteric, or hepatic arteries. Classic “string of beads” appearance is a clue.
• Biopsy: gold standard. A biopsy of affected tissue (skin, nerve, muscle) shows necrotizing arteritis with fibrinoid change. Sometimes you need deep biopsies to capture medium-sized vessels.
• Rule out mimics: lupus vasculitis, rheumatoid vasculitis, other ANCA-associated vasculitis, and infections that can cause secondary vasculitis.

Typical pathway: you suspect PAN based on systemic symptoms + elevated inflammatory markers, then check viral serologies, proceed with imaging, and finish with biopsy if possible. In certain life-threatening cases, treatment may begin before biopsy results, but ideally you want histologic confirmation.

Which Doctor Should You See for Polyarteritis Nodosa?

Wondering which doctor to see for polyarteritis nodosa? Your first stop is usually a primary care physician (internist), who can run basic tests and refer you. From there:

• Rheumatologist: specializes in vasculitis and autoimmune conditions—often the main specialist for ongoing management.
• Nephrologist: if you have hypertension or signs of renal artery involvement, you may also see a kidney specialist.
• Neurologist: for mononeuritis multiplex or other nerve issues.
• Gastroenterologist: if GI symptoms are prominent (bleeding, severe pain).

In urgent cases—acute abdomen, limb ischemia, heart involvement—head to the emergency department right away; don’t wait for a telemedicine appointment. That said, online consultations can be useful for second opinions, interpreting lab results, or asking follow-up questions after your in-person visit. Just remember: telemedicine supplements but cannot fully replace an in-depth physical exam when your life might be on the line.

Treatment Options and Management

Evidence-based treatment for polyarteritis nodosa typically involves immunosuppression:

• Glucocorticoids: High-dose prednisone (1 mg/kg daily) to induce remission, then taper over months. Side effects include weight gain, osteoporosis, mood swings.
• Cyclophosphamide: For severe or life-threatening cases (e.g., renal, GI, cardiac involvement), given as monthly IV pulses or daily oral dosing.
• Azathioprine or Methotrexate: Maintenance therapy once remission achieved.
• Antiviral therapy: For hepatitis B–associated PAN, treat with lamivudine or entecavir before initiating immunosuppression to reduce viral load.
• Supportive care: blood pressure control (ACE inhibitors, ARBs), neuropathic pain management (gabapentin), physical therapy for muscle weakness.

In rare scenarios, plasma exchange has been tried, but data are limited. Treatment durations often span at least 12–18 months, with close monitoring for relapses and drug toxicity.

Prognosis and Possible Complications

The prognosis of polyarteritis nodosa has improved since the advent of modern immunosuppression. Decades ago, untreated PAN had a five-year survival rate below 20%. Now, with aggressive therapy, five-year survival exceeds 75–80% for most patients.

Complications, particularly if diagnosis or treatment is delayed, include:

• Renal failure: from persistent ischemia or hypertension
• GI ischemia or perforation: surgical emergencies
• Peripheral neuropathy: may lead to permanent deficits
• Cardiac involvement: myocardial infarction or heart failure in severe cases
• Infection: from immunosuppressive therapy

Factors associated with worse outcomes include advanced age, severe gastrointestinal involvement, central nervous system disease, and high hepatitis B viral load. Early diagnosis and appropriate therapy remain key to better long-term results.

Prevention and Risk Reduction

Because most cases of polyarteritis nodosa are idiopathic, primary prevention is challenging. However, there are pragmatic steps to reduce risk and catch disease early:

• Hepatitis B vaccination: Reduces risk of HBV-associated PAN.
• Early treatment of infections: Prompt and adequate therapy for hepatitis or streptococcal infections may prevent immune complex–driven vasculitis.
• Regular health checkups: Annual physicals with basic labs can flag unexplained inflammation (elevated ESR, CRP).
• Lifestyle measures: smoking cessation to minimize vascular stress, balanced diet, moderate exercise.

Secondary prevention involves close follow-up with your rheumatologist, adherence to immunosuppressive regimens, and monitoring for drug-related side effects (e.g., bone density scans for glucocorticoid users). Screening for hypertension and renal function helps catch complications early.

Myths and Realities

There’s a lot of confusion about polyarteritis nodosa floating around—so let’s bust some myths:

• Myth: “PAN always affects the lungs.” Reality: Almost never—if you see lung lesions, think about other vasculitides like granulomatosis with polyangiitis.
• Myth: “You’ll always find ANCA in PAN.” Reality: Classic PAN is ANCA-negative. If ANCA is positive, re-evaluate the diagnosis.
• Myth: “Once treatment stops, you’re cured.” Reality: Relapses occur in up to 30% of patients; maintenance therapy may be needed.
• Myth: “Only older people get PAN.” Reality: Peak is 40–60, but it can occur in children or young adults, especially with secondary causes.
• Myth: “Diet and herbal supplements can cure it.” Reality: No credible evidence supports miracle diets; stick to proven medical therapies.

By separating hype from fact, you’re in a better position to navigate this complex disease and advocate for sound medical care.

Conclusion

Polyarteritis nodosa is a challenging but treatable form of systemic vasculitis affecting medium-sized arteries. Key points: early recognition of variable symptoms, confirmation through serology, imaging and biopsy, and prompt immunosuppressive therapy can markedly improve prognosis. While some uncertainties around causes remain, evidence supports aggressive management of inflammation combined with targeted antiviral therapy when hepatitis B is involved. If you suspect PAN, don’t hesitate to consult qualified professionals—a multidisciplinary approach often ensures the best outcomes. Stay vigilant, and remember that timely medical care can make all the difference.

Frequently Asked Questions

• Q1: What age group does polyarteritis nodosa affect?
  A1: PAN most commonly hits adults 40–60 years old but can occur at any age, including childhood.
• Q2: Is PAN hereditary?
  A2: There’s no direct inheritance pattern, though certain HLA types may slightly increase risk.
• Q3: How quickly does PAN progress?
  A3: It varies—some get acute, rapid organ involvement, others have a slow, chronic course.
• Q4: Can hepatitis B cause PAN?
  A4: Yes, about 10% of cases are hepatitis B–associated due to immune complex deposition.
• Q5: Are ANCA tests positive in PAN?
  A5: No, classic PAN is ANCA-negative, which helps distinguish it from other vasculitides.
• Q6: What’s the gold standard for diagnosis?
  A6: Tissue biopsy showing necrotizing arteritis; angiography is also highly suggestive.
• Q7: How is PAN treated?
  A7: High-dose steroids plus cyclophosphamide for severe cases, then maintenance with azathioprine or methotrexate.
• Q8: What are common PAN complications?
  A8: Renal failure, GI perforation, neuropathy, cardiac ischemia, and infection from immunosuppression.
• Q9: Is PAN curable?
  A9: There’s no guaranteed cure; many achieve remission, but relapses can occur, requiring ongoing care.
• Q10: Can lifestyle changes prevent PAN?
  A10: No definitive prevention, but HBV vaccination and infection control lower specific risks.
• Q11: Which specialist treats PAN?
  A11: Primarily a rheumatologist, with possible input from nephrologists, neurologists, or GI specialists.
• Q12: When should I seek emergency care?
  A12: Sudden severe abdominal pain, signs of limb ischemia, or acute chest pain warrant immediate ER visit.
• Q13: Is telemedicine useful for PAN?
  A13: Yes for follow-up, lab reviews, second opinions, but not a substitute for urgent physical exams.
• Q14: Can children get PAN?
  A14: Rare, but pediatric-onset PAN exists and often involves skin, joints, and sometimes kidneys.
• Q15: What’s the long-term outlook?
  A15: With timely treatment, 5-year survival is 75–80%, though monitoring for relapse and treatment side effects is crucial.